Next Article in Journal
The Multi-Functional Calcium/Calmodulin Stimulated Protein Kinase (CaMK) Family: Emerging Targets for Anti-Cancer Therapeutic Intervention
Next Article in Special Issue
Optimization of the Automated Synthesis of [11C]mHED—Administered and Apparent Molar Activities
Previous Article in Journal
Aptamer-Based Diagnostics and Therapeutics
Previous Article in Special Issue
Development of [131I]I-EOE-TPZ and [131I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2019, 12(1), 7; https://doi.org/10.3390/ph12010007

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging

1
Department of Oncology, Division of Oncological Imaging, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
2
Division of Nuclear Medicine, Department of Radiology, The University of Michigan Medical School, Ann Arbor, MI, 48109, USA
3
The Interdepartmental Program in Medicinal Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
4
Department of Nuclear Medicine, Ludwig-Maximilians-University of Munich, Marchioninistrasse 15, Munich 81377, Germany
5
Program in Neurosciences and Mental Health, Hospital for Sick Children and Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada M5G 0A4
6
McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, 3801 University Street, Montreal, QC H3A 2B4, Canada
7
Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, Heidelberg 69120, Germany
8
Translational Neuroimaging Laboratory, McGill Centre for Studies in Aging, Douglas Mental Health University Institute, Montreal, QC H4H 1R3, Canada
9
Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, 68167 Mannheim, Germany
10
Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany
11
Jewish General Hospital, Lady Davis Institute, Montreal, QC HT3 1E2, Canada
12
Azrieli Centre for Neuro-Radiochemistry, Research Imaging Centre, Centre for Addiction and Mental Health, Toronto, ON M5T 1L8, Canada
13
Department of Psychiatry, University of Toronto, Toronto, ON M5T 1R8, Canada
*
Authors to whom correspondence should be addressed.
Received: 27 November 2018 / Revised: 17 December 2018 / Accepted: 17 December 2018 / Published: 3 January 2019
Full-Text   |   PDF [2731 KB, uploaded 3 January 2019]   |  
  |   Review Reports

Abstract

The tropomyosin receptor kinases family (TrkA, TrkB, and TrkC) supports neuronal growth, survival, and differentiation during development, adult life, and aging. TrkA/B/C downregulation is a prominent hallmark of various neurological disorders including Alzheimer’s disease (AD). Abnormally expressed or overexpressed full-length or oncogenic fusion TrkA/B/C proteins were shown to drive tumorigenesis in a variety of neurogenic and non-neurogenic human cancers and are currently the focus of intensive clinical research. Neurologic and oncologic studies of the spatiotemporal alterations in TrkA/B/C expression and density and the determination of target engagement of emerging antineoplastic clinical inhibitors in normal and diseased tissue are crucially needed but have remained largely unexplored due to the lack of suitable non-invasive probes. Here, we review the recent development of carbon-11- and fluorine-18-labeled positron emission tomography (PET) radioligands based on specifically designed small molecule kinase catalytic domain-binding inhibitors of TrkA/B/C. Basic developments in medicinal chemistry, radiolabeling and translational PET imaging in multiple species including humans are highlighted. View Full-Text
Keywords: tropomyosin receptor kinase; positron emission tomography; neurodegeneration; oncogenic fusions tropomyosin receptor kinase; positron emission tomography; neurodegeneration; oncogenic fusions
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Schirrmacher, R.; Bailey, J.J.; Mossine, A.V.; Scott, P.J.H.; Kaiser, L.; Bartenstein, P.; Lindner, S.; Kaplan, D.R.; Kostikov, A.; Fricker, G.; Mahringer, A.; Rosa-Neto, P.; Schirrmacher, E.; Wängler, C.; Wängler, B.; Thiel, A.; Soucy, J.-P.; Bernard-Gauthier, V. Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging. Pharmaceuticals 2019, 12, 7.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top